Resiniferatoxin
Phase 1Small molecule
Resiniferatoxin is one of 4 small molecule programs targeting Pain. It is currently in Phase 1.
2
Indications
9
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Neuroma
#DrugCompanyPhaseTrials
1IC-Green
PProvepharm SAS
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Medrol
PfizerPreclinical
Resiniferatoxin
SSorrento Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoarthritis4 trials
Cancer Pain2 trials
Advanced Cancer1 trial
Pain1 trial
An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
Not yet recruiting·NNational Institute of Neurological Disorders and Stroke (NINDS)·Preclinical·NCT02522611·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Resiniferatoxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSorrento Therapeutics, Inc.